Skip to main content

Table 3 Summary of pre-treatment imaging diagnosis, baseline symptoms, and pre-treatment medical management in P1–P5

From: Yttrium-90 radioembolization as a possible new treatment for brain cancer: proof of concept and safety analysis in a canine model

Patient

Official diagnostic basis for inclusion

Baseline symptoms

Medical management at seizure onset

P1

Highly vascular neoplasm with a component of hemorrhage vs vascular anomaly

First seizure 1 month prior to 90Y-RE with compulsive circling to the right. At presentation prior to 90Y-RE, there was a preference for turning to the right vs left. Remainder of neurological exam was normal.

Phenobarbital, low-dose prednisone

P2

Astrocytoma*

First seizure 3 months prior to 90Y-RE. No neurological deficits on presentation prior to treatment.

Levetiracetam

P3

Low-grade glioma

First seizure 3 months prior to 90Y-RE. No neurological deficits on presentation prior to treatment.

Levetiracetam, low-dose prednisone

P4

Glial neoplasm

First seizure 2 months prior to 90Y-RE. At presentation prior to 90Y-RE, there was a left hindleg slight proprioceptive delay.

Levetiracetam, gabapentin, low-dose prednisone

P5

Astrocytoma*

First seizure 1 month prior to 90Y-RE. At presentation prior to 90Y-RE, there were left side proprioceptive defects and left visual deficit and circling to the right.

Levetiracetam, low-dose prednisone

  1. *Proven from post-mortem pathology